Javadi Alireza 4

What Happened

• Alireza Javadi, Chief Technical Officer of Rani Therapeutics (RANI), disposed of a total of 695 shares in two transactions tied to the settlement/release of restricted stock units. On 2026-03-27 he sold 386 shares in an open-market or private sale at $0.78 each ($301.08). On 2026-06-27, 309 shares were disposed at $0.74 each ($228.66) to satisfy tax-withholding obligations. Total proceeds were about $529.74.

Key Details

• Transaction types: S (sale/open market or private sale) on 2026-03-27; F (payment of exercise price or tax liability / withholding) on 2026-06-27.
• Prices and amounts: 386 shares @ $0.78 (≈$301.08); 309 shares @ $0.74 (≈$228.66); total ≈$529.74.
• Report filed: Form 4 filed 2026-07-21 for report period 2026-03-27; filing was reported late (footnote cites inadvertent administrative oversight).
• Footnotes: Transactions relate to settlement/release of restricted stock units; some shares were withheld or surrendered to the issuer to satisfy tax withholding.
• Shares owned after the transactions: not disclosed in the provided filing.

Context

• These transactions appear routine: the second disposal was to cover tax-withholding tied to RSU settlement (a common administrative transaction), and the first was an open-market or private sale. Such sales/withholdings typically reflect administrative or tax needs rather than a clear buy/sell signal about company prospects. The filing delay was noted by the insider.